UK-Japan FTA: Banishing UK Pharma’s Brexit Blues
The signing of an agreement on the terms of a future trade relationship between Japan and the UK has been welcomed by the UK pharma industry, which counts Japan as…
Address: Boehringer Ingelheim Limited, Ellesfield Avenue, Bracknell, Berkshire, RG12 8YS, United Kingdom ,United Kingdom
Tel: +44 (0) 1344 424 600
Web: http://www.boehringer-ingelheim.co.uk/
Boehringer Ingelheim is a family owned company whose distinctly independent structure means that we are not constrained by the short-term needs of individual shareholders and can focus on the future with long-term strategies of vision and leadership. Boehringer Ingelheim was founded in 1885 by Albert Boehringer and remains a familyowned company. Today we are the fastest growing company amongst the world’s 15 leading pharmaceutical companies.
Annual sales are €12.7 billion worldwide (2009) and 21% of the net sales from its Prescription Medicine business is invested into research and development. The company now employ more than 41,500 people and is committed to remaining family-owned. Albert’s great grandson, Christian Boehringer, is the Chair of the Shareholders’ Committee which manages 142 affiliated companies in 50 countries around the globe. Our headquarters remain in Ingelheim, near Frankfurt in Germany.
Boehringer Ingelheim’s vision, ‘Value through Innovation’, mirrors the founder’s own belief in the importance of innovative thinking and that, as well as being financially profitable, products should be pioneering and of genuine benefit to patients. This independent status frees the company from stock market expectations, and allows for long-term strategies, rather than short-term priorities.
In the United Kingdom, Boehringer Ingelheim was established in 1962 and is one of the fastest growing pharmaceutical companies in the UK, with total sales of £388 million in 2009 (independent audit). The business focuses on clinical research, data management, sales and marketing.
Boehringer Ingelheim is involved in three key healthcare areas: Prescription Medicines, Over-The-Counter (OTC) products and Animal Health. In each sector, the company has world-class medicines to treat patients.
The company has a reputation for providing effective products for the treatment of chronic obstructive pulmonary disease (COPD), heart attack, secondary stroke prevention and treatment, high blood pressure, thromboembolic disease, HIV/AIDS, Parkinson’s disease, arthritis and pain relief in cancer.
These products are supported by a wide range of services, designed to help the medical profession deliver the best possible healthcare to patients.
This underlines Boehringer Ingelheim’s commitment to improving health and quality of life in the UK.
The signing of an agreement on the terms of a future trade relationship between Japan and the UK has been welcomed by the UK pharma industry, which counts Japan as…
US Merck (MSD globally) is following through on a 2017 commitment to invest in a new early research hub in central London, with plans to open the ‘London Discovery Research…
Jameel Zayed of Leyton, the UK’s leading innovation funding consultancy, highlights the British pharmaceutical industry’s rapid response to COVID-19 and the three ways in which the sector is driving national…
Below we highlight some recent developments in pharma and healthcare in the UK, including drug shortages in British intensive care units (ICUs), COVID-19 drug trials, biotech deals and market access…
The world’s two leading vaccine producers, GSK of the UK and France’s Sanofi, last week announced that they are working together to develop a vaccine for the novel coronavirus (COVID-19);…
With Brexit now confirmed, the UK government has been playing up the country’s scientific credentials. The aim is to cement the UK’s position as one of the world’s top life…
Friday January 31 2020 was officially dubbed “Brexit Day” as the UK finally left the EU, following British Prime Minister Boris Johnson’s sweeping election victory on a promise to “Get…
Although biotech financing in the UK took a hit last year in large part thanks to uncertainty around Brexit, 2019 was still the British industry’s third-best year on record. …
GW Pharmaceuticals reports that sales of its CBD drug Epidiolex more than doubled in the second quarter of 2019, demonstrating that cannabinoid-based medicines can be highly profitable and potentially blazing…
Formed in 2015, listed UK start-up Amryt targets rare diseases with high unmet medical need. With one commercial asset on the market, a strong pipeline of development assets and a…
Hopes have been raised of a cure for AIDS after a patient in London became free of the HIV virus following a bone marrow transplant. Although it is not…
Founded in 1998, GW Pharmaceuticals is a British biopharmaceutical company, best known for being the only company with a license to cultivate cannabis in the UK. True pioneers, they are…
See our Cookie Privacy Policy Here
